NASDAQ:PRFX - PainReform Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$6.49
▲ +0.19 (3.02%)
1 month | 3 months | 12 months
Get New PainReform Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRFX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRFX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for PainReform in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $6.49.
Buy
The current consensus among 1 investment analysts is to buy stock in PainReform.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/31/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/29/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/28/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/30/2020Maxim GroupInitiated CoverageBuyLow
i
(Data available from 2/27/2016 forward)
PainReform logo
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of products for the treatment of pain in Israel. It develops PRF-110, a product based on local anesthetic ropivacaine, which completed Phase II clinical study in hernia repair. The company was founded in 2007 and is headquartered in Herzeliya, Israel.
Read More

Today's Range

Now: $6.49
$5.87
$6.68

50 Day Range

MA: $4.95
$4.12
$6.82

52 Week Range

Now: $6.49
$3.82
$7.85

Volume

182,964 shs

Average Volume

245,985 shs

Market Capitalization

$56.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of PainReform?

The following Wall Street research analysts have issued research reports on PainReform in the last twelve months: Maxim Group.
View the latest analyst ratings for PRFX.

What is the current price target for PainReform?

0 Wall Street analysts have set twelve-month price targets for PainReform in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for PainReform in the next year.
View the latest price targets for PRFX.

What is the current consensus analyst rating for PainReform?

PainReform currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PRFX will outperform the market and that investors should add to their positions of PainReform.
View the latest ratings for PRFX.

What other companies compete with PainReform?

How do I contact PainReform's investor relations team?

The company's listed phone number is 972 9 960 1901 and its investor relations email address is [email protected] The official website for PainReform is www.painreform.com.